interleukin-2 + azacitidine + cyclophosphamide + sirolimus

A combination therapy regimen consisting of interleukin-2, azacitidine, cyclophosphamide, and sirolimus. This combination likely leverages multiple mechanisms of action: * **Azacitidine:** a hypomethylating agent that has been studied in various combinations for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). * **Cyclophosphamide:** an alkylating agent used to treat various cancers including lymphomas, leukemias (including AML), multiple myeloma, and breast cancer. It works by slowing or stopping cancer cell growth and can also be used as an immunosuppressant. * **Sirolimus:** an immunosuppressant that works by inhibiting T-lymphocyte activation and proliferation by inhibiting the mammalian target of rapamycin (mTOR). * **Interleukin-2:** a cytokine that plays a key role in immune system function, particularly in the growth and activity of T cells, suggesting it acts as an immune system modulator. The combination may be investigated for treatment of hematologic malignancies, particularly in settings where immune modulation and cytotoxic effects are both desired, or potentially in transplantation settings.

Other names

interleukin-2 + azacitidine + cyclophosphamide + sirolimusIL-2 + azacitidine + cyclophosphamide + sirolimusVidaza + Cytoxan + sirolimus + IL-2